Immune cell changes in autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how certain immune cells change in the blood before and after treatment for autoimmune hemolytic anemia (AIHA). Doctors want to see if these cell levels can help predict or monitor the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with autoimmune hemolytic anemia (a condition where your body's immune system attacks your red blood cells).
- You have not started any treatment for this condition yet.
- You are not pregnant or breastfeeding.
- You do not have a blood cancer (like leukemia or lymphoma).
- Your anemia is not caused by an immune reaction from a blood transfusion or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
This trial tests a new cell treatment called YTS109 for people with autoimmune hemolytic anemia (AIHA) that has not improved after several standard treatments. The goal is to see if this treatment can help control the disease.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.